Oppenheimer Upgrades Inovio Pharmaceuticals (INO) to Outperform

Oppenheimer analyst Jay Olson upgraded Inovio Pharmaceuticals (NASDAQ: INO) from Outperform to Outperform with a price target of $13.00.

The analyst commented: "Inovio reported 3Q25 results with $21.2M OpEx and $50.8M cash balance, which 1) support runway into 2Q26 given ~$22M cash burn in 4Q25 and 2) could be bolstered further by INO's recently proposed public offering. Importantly, INO recently accomplished a key milestone with the completion of rolling BLA submission for lead INO-3107 in RRP alongside a request for priority review. If granted priority review (as done with Precigen's PRGN-2012), INO-3107 could be approved as early as mid-2026, with commercial preparations ongoing to support potential launch thereafter. We continue to see INO-3107's key differentiation versus Papzimeos providing several commercial advantages and believe INO's potential approval/launch could be a key point of inflection as the company becomes commercial-stage. We update our model with actuals and maintain Outperform."

For an analyst ratings summary and ratings history on Inovio Pharmaceuticals click here. For more ratings news on Inovio Pharmaceuticals click here.

Shares of Inovio Pharmaceuticals closed at $2.15 yesterday.

You May Also Be Interested In

• Barclays Upgrades Castellum AB (CAST:SS) (CWQXF) to Equalweight
• Jefferies Upgrades Agnico-Eagle Mines Ltd. (AEM) to Buy
• UBS Upgrades Charoen Pokphand Foods (CPF:TB) to Buy